Pawlotsky Jean-Michel
Department of Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France.
Inserm U955, Créteil, France.
Clin Infect Dis. 2020 Nov 19;71(16):2191-2194. doi: 10.1093/cid/ciaa587.
December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is available to treat this infection that has already killed > 310 000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the life cycle of many coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at risk of severe forms of SARS-CoV-2 infection.
2019年12月，一种严重程度各异的新型肺炎疫情出现，即2019冠状病毒病（COVID-19），它由一种新发现的冠状病毒——严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起。目前尚无治疗这种感染的有效方法，该感染已在全球导致超过31万人死亡。本观点总结了支持使用阿利司匹韦治疗COVID-19的有力科学依据，阿利司匹韦是环孢素A的一种非免疫抑制类似物，具有强大的亲环素抑制特性，已进入3期临床开发阶段。这些依据包括许多冠状病毒（包括严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒）生命周期对亲环素的强烈依赖性，以及临床前数据表明阿利司匹韦在包括SARS-CoV-2在内的各种冠状病毒感染模型中具有强大的抗病毒和细胞保护特性。应立即对患有严重SARS-CoV-2感染或有感染风险的患者进行阿利司匹韦的病毒学和临床终点测试。
